Status:
UNKNOWN
Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations
Lead Sponsor:
National Jewish Health
Collaborating Sponsors:
Cystic Fibrosis Foundation
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
Pulmonary exacerbations (PEx) are key events that lead to a decline in health status among CF patients, with many never recovering to baseline health. With the advancement of new CFTR modulators and o...
Eligibility Criteria
Inclusion
- CF patients 18 years or older who are hospitalized for IV treatment of an acute PEx
- Chronically infected with Pseudomonas aeruginosa and/or Staphylococcus aureus
- Can produce sputum
- Can provide written consent
- Willing to comply with study procedure
Exclusion
- Subjects who are not colonized with Pseudomonas aeruginosa and/or Staphylococcus aureus
- The presence of a condition or abnormality that, in the opinion of the Principal Investigator, would compromise the safety of the patient or the quality of the data
Key Trial Info
Start Date :
February 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04341532
Start Date
February 20 2020
End Date
December 1 2025
Last Update
September 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Jewish Health
Denver, Colorado, United States, 80206